Nectar Raises Over $24M In Funding To Scale Personalized Allergy Care Platform Nationally

Dec 20, 2022•almost 3 years ago

Amount Raised

$24 Million

New YorkInformation Technology

Investors

Obvious VenturesHarmony Partners

Description

Nectar, an innovative and comprehensive allergy care platform, announced today its $16.5 million Series A round led by Harmony Partners, with meaningful participation from founding partners Juxtapose and Obvious Ventures, who co-built the company with Founding CEO Kenneth Chahine, Ph.D.

Company Information

Company

Nectar Allergy

Location

30 COOPER SQUARE

New York, New York, United States

About

We’re providing revolutionary allergy care to free the world from allergies. Our platform connects people directly to physicians and pharmacists who create customized treatment plans that get to the root cause of allergies. The end result: no more days derailed by allergy attacks.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends